Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Nissen, Steven E.; Lincoff, A. Michael; Brennan, Danielle M.; Ray, Kausik K.; Mason, Denise; Kastelein, John J.P.; Thompson, Paul D.; Libby, Peter; Cho, Leslie; Plutzky, Jorge; Bays, Harold; Moriarty, Patrick M.; Menon, Venu; Grobbee, Diederick E.; Louie, Michael J.; Chen, Chien-Feng; Li, Na; Bloedon, LeAnne T.; Robinson, Paula; Horner, Maggie; Sasiela, William J.; McCluskey, Jackie; Davey, Deborah; Fajardo-Campos, Pedro; Petrović, Predrag; Fedačko, Ján; Żmuda, Witold; Lukyanov, Yury; Nicholls, Stephen J.

doi:10.1056/nejmoa2215024

Cited by 370 publications

(355 citation statements)

References 20 publications

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…2 After excluding contributing factors, such as vitamin D deficiency and hypothyroidism, 2 a 1-month drug holiday is recommended followed by a rechallenge to see if symptoms return. If symptoms return, different strategies may be tried, such as ultralow-dose statin therapy, ezetimibe or bemedoic acid therapy, 16 or use of nutraceuticals such as beta-glucan.…”

mentioning

confidence: 99%

For Your Eyes Only: 007 Tips for the Management of Cardiovascular Risk Factors in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Tervaert

2023

J Rheumatol

View full text Add to dashboard Cite

Premature atherosclerosis has been observed during the course of different systemic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).1-3As a result, cardiovascular (CV) events, including myocardial infarction, stroke, heart failure, coronary artery disease, and death, occur 1.65 to 3 times more commonly in patients with AAV as compared to the general population, and the risk appears to be highest in the first year following diagnosis.3

show abstract

mentioning

confidence: 99%

For Your Eyes Only: 007 Tips for the Management of Cardiovascular Risk Factors in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Tervaert

2023

J Rheumatol

View full text Add to dashboard Cite

show abstract

“…Trials show an average LDL reduction of 16%-23% following 3 months of therapy [2][3][4] . Furthermore, the CLEAR Outcomes trial recently showed that use of bempedoic acid resulted in a statistically significant reduction in the risk of major cardiovascular events [5] . Bempedoic acid was approved in 2020 by the EMA for use in Europe.…”

Section: Discussionmentioning

confidence: 99%

Severe hypertriglyceridemia after use of bempedoic acid

Bovy

Bogaert²

2023

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

Bempedoic is a new drug for the management of hypercholesterolemia, approved since 2020 by the EMA for use in Europe. In this case report, we describe a 65-year-old woman with sudden worsening of hypertriglyceridemia after the introduction of bempedoic acid. Triglyceride levels normalized quickly on withdrawal of the drug. With this case report, we want to reveal a possible association between bempedoic acid and the paradoxical occurrence of hypertriglyceridemia. Furthermore, we want to emphasize the limited evidence regarding the use of bempedoic acid in patients with pre-existing hypertriglyceridemia.

show abstract

“…Initial animal model studies suggest a potential favorable impact of this drug on the pathogenesis of atherosclerosis [ 161 , 162 ]. Recently published results of the CLEAR outcome trial reported a beneficial effect of Bempedoic acid on the reduction in major adverse cardiovascular events, including death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization [ 163 ].…”

Section: Novel Ldl-c Lowering Drugsmentioning

confidence: 99%

Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review

et al. 2023

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) are the leading cause of death worldwide. Since the establishment of the “lipid hypothesis”, according to which, cholesterol level is directly correlated to the risk of CVD, many different lipid-lowering agents have been introduced in clinical practice. A majority of these drugs, in addition to their lipid-lowering properties, may also exhibit some anti-inflammatory and immunomodulatory activities. This hypothesis was based on the observation that a decrease in lipid levels occurs along with a decrease in inflammation. Insufficient reduction in the inflammation during treatment with lipid-lowering drugs could be one of the explanations for treatment failure and recurrent CVD events. Thus, the aim of this narrative review was to evaluate the anti-inflammatory properties of currently available lipid-lowering medications including statins, ezetimibe, bile acid sequestrants (BAS), proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, fibrates, omega-3 fatty acids, and niacin, as well as dietary supplements and novel drugs used in modern times.

show abstract

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Cited by 370 publications

References 20 publications

For Your Eyes Only: 007 Tips for the Management of Cardiovascular Risk Factors in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

For Your Eyes Only: 007 Tips for the Management of Cardiovascular Risk Factors in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Severe hypertriglyceridemia after use of bempedoic acid

Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review

Contact Info

Product

Resources

About